+

WO1994026259A1 - Prevention ou inversion chimique de la cataracte par inhibiteurs de separation de phases - Google Patents

Prevention ou inversion chimique de la cataracte par inhibiteurs de separation de phases Download PDF

Info

Publication number
WO1994026259A1
WO1994026259A1 PCT/US1993/004452 US9304452W WO9426259A1 WO 1994026259 A1 WO1994026259 A1 WO 1994026259A1 US 9304452 W US9304452 W US 9304452W WO 9426259 A1 WO9426259 A1 WO 9426259A1
Authority
WO
WIPO (PCT)
Prior art keywords
cataract
lens
phase separation
coenzyme
animals
Prior art date
Application number
PCT/US1993/004452
Other languages
English (en)
Inventor
John I. Clark
George B. Benedek
George M. Thurston
Xiao-Yan Li
Original Assignee
Oculon Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oculon Corporation filed Critical Oculon Corporation
Priority to AU43723/93A priority Critical patent/AU4372393A/en
Priority to PCT/US1993/004452 priority patent/WO1994026259A1/fr
Publication of WO1994026259A1 publication Critical patent/WO1994026259A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds

Definitions

  • the present invention relates generally to compositions for the prevention or inhibition of cataracts, and more specifically, to compositions containing coenzyme A or derivatives or metabolites thereof.
  • Cataract is the general term for any pathological condition in which the normal transparency of the ocular lens is substantially diminished. More than one million cataract extractions are performed annually in the United States, and it is estimated that 5 to 10 million individuals become visually disabled each year due to cataracts.
  • cataracts may develop at any time in life, even before birth.
  • Risk factors for cataract formation include metabolic disorders (e.g., diabetes), exposure to toxic agents in the environment (e.g., ultraviolet radiation, ionizing radiation), drug side effects, and inherited traits.
  • metabolic disorders e.g., diabetes
  • toxic agents in the environment e.g., ultraviolet radiation, ionizing radiation
  • anti-cataract agents development of anti-cataract agents has been hampered, in part, by the lack of a good animal model of human cataract. Consequently, putative anti-cataract agents may be evaluated for efficacy in a variety of different models which, to the extent that they are understood at all, are thought to occur by different mechanisms.
  • radiation-induced cataract is generally believed to result from oxidative damage to the lens.
  • Diabetic cataract is thought to be due to the accumulation of polyols (such as sorbitol) in the lens, resulting from increased activity of the enzyme aldose reductase.
  • Selenite- induced cataract is thought to be due to activation of a class of Ca 2+ -dependent proteases in the lens.
  • the lens exhibits a high degree of regularity, consisting of fiber cells with hexagonal cross sections packed together to create a very regular parallel array of fiber cells which stretch from anterior to posterior pole.
  • the lens fiber cells lose all intracellular organelles that could contribute to light scattering during the process of differentiation and the cytoplasmic protein concentration increases markedly.
  • Approximately 35% to 60% of the total mass of the lens consists of structural proteins, the remainder being water. More than 90% of the total lens protein consists of alpha, beta, and gamma crystallins, a group of structural proteins found at extremely high concentrations (in excess of 300 mg/ml) in the lens cell cytoplasm.
  • the cytoplasmic concentration of the crystallins throughout the lens occurs along a continuous radial concentration gradient, in which the concentration is greatest in cells at the nucleus and decreases in peripheral cells of the lens cortex.
  • the crystallin distribution determines the mean index of refraction and index gradient, which are in turn responsible for the special optical properties of the animal lens.
  • An important optical property is lens transparency.
  • incident light is scattered in all directions by the macromolecular constituents of the lens. If the individual wavelets of the scattered light interfere destructively with one another, the lens is transparent. Destructive interference takes place in the normal lens because of the existence of short range order in the relative positions of the crystallins. If the uniformity of the protein concentration is sufficiently perturbed, a substantial fraction of the incident light is scattered in directions away from the forward direction. The scattering results in a distortion of the wave front of the transmitted light, and in opacity of the lens tissue. The opacity is responsible for visual impairment in cataract diseases.
  • Cataracts are the leading cause of blindness in humans worldwide, and surgery remains the primary form of treatment. Cataracts in animals also pose a significant veterinary problem. To date, a compound for in vivo administration to humans or other animals has not been demonstrated to prevent cataracts of diverse origin. Further, in vivo reversal of the initiation of cataract formation has not been successfully demonstrated.
  • the present invention provides an in vivo method and pharmaceutical reagents for preventing abnormal increases in phase separation temperature and prevention of cataract formation.
  • the pharmaceutical reagents are able to diffuse into the lens and exert a prophylactic or therapeutic anti-cataractic effect over a reasonable period of time. Desirable reagents do not change the eye color or viscoelastic properties of the lens in a manner detrimental to visual acuity.
  • the reagents are applied locally (Le., topically) to minimize the effective dose and possible side effects, but may also be administered systemically (e.g., orally or by injection).
  • the specific effect of the reagents is believed to be an inhibition to changes in spatial fluctuations in the index of refraction by maintaining the short range order in the lens proteins. This is accompanied by an inhibition to an increase in the phase separation temperature and by a suppression of the formation of high molecular weight aggregates.
  • Temperatures for which phase separation occurs can be determined from a coexistence curve distinguishing the homogeneous from the heterogeneous phases. At temperatures outside (above) the coexistence curve, the lens cytoplasm exists as a homogeneous, transparent phase. At temperatures within (below) the coexistence curve, the cytoplasm separates into regions which are rich and poor in the constituent proteins. These regions, which have different indices of refraction, scatter light strongly and produce opacification.
  • Pathologic cataracts are characterized by disruption of membrane structure, the formation of high molecular-weight aggregates, and functional deterioration. These changes occur well after the first changes in phase separation temperature occurs.
  • the phase separation temperature serves as a useful indicator of the earliest stages of cataract formation.
  • the presence of high molecular weight aggregates, which scatter light and cause opacification can be determined from the measurement of the intensity autocorrelation function of laser light scattered from the lens, where the width of the scattered light spectrum or the reciprocal of the correlation time of the scattered light intensity fluctuation decreases with the concentration of high molecular weight aggregates.
  • Examples of reagents or phase separation inhibitors (PSIs) according to the present invention which have been demonstrated to meet the desired criteria and are useful in methods of treating and preventing cataracts in the lens of a mammal include phosphorothioate compounds of the general formula RNHR1SPO3H2, in which R is hydrogen, an alkoxy group containing 1 to 6 carbon atoms or the group R2NH(C n H2 n )-, in which R2 is hydrogen or an alkyl group containing 1 to 6 carbon atoms and n has a value of from 2 to 6, Rj is an optionally substituted alkylene group having from 1 to 6 carbon atoms, and hydrates or alkali metal salts thereof.
  • R is hydrogen, an alkoxy group containing 1 to 6 carbon atoms or the group R2NH(C n H2 n )-
  • R2 is hydrogen or an alkyl group containing 1 to 6 carbon atoms and n has a value of from 2 to 6
  • Rj is
  • Particularly preferred phosphorothioates are S-3-(amino-2-hydroxypropyl) phosphorothioate (WR- 77913) and S-2-(3-aminopropylamino) ethyl phosphorothioate (WR-2721).
  • Other compounds include succinimides and derivatives thereof, where preferred compounds are selected from the group consisting of succinimide, N- hydroxysuccinimide (NHS), and ethosuximide.
  • Another group of reagents useful as pharmaceutical compositions inhibiting or reversing cataractogenesis comprises pantethine, pantetheine, pantothenic acid, and panthenol. Still other compounds include cysteamine.
  • An additional class of reagents or PSIs includes coenzyme A (CoA) and various derivatives, modifications, and/or metabolites thereof.
  • Derivatives of CoA include acetyl CoA, malonyl CoA, methylmalonyl CoA, succinyl CoA, propionyl CoA, CoA glutathione disulfide and oxidized CoA.
  • Various modifications to CoA may be made by substitution of various moieties within the CoA molecule. Metabolites of CoA may also function as reagents within the scope of the present invention.
  • the reagents of the present invention may be utilized in the treatment methods herein described in a variety of ways, including topical administration as well as systemic or parenteral administration.
  • the subjects which may be benefited by the treatment methods of the invention include a variety of mammals which are susceptible to cataract development, such as equine, canine, and feline species, as well as humans.
  • Figure 1 is a photograph of control rat eyes compared to cataractous rat eyes, rat eyes treated with WR-77913 (PSI A), and rat eyes treated with pantethine (PSI B).
  • the top row is a photograph of the eye of the animals and the row below is a slit-lamp photograph of the same eye.
  • the first column is a normal eye of a control rat without any treatment.
  • the second column is a cataract-induced eye approximately 150 days following irradiation. The last two columns show the eyes of animals that were administered PSI A or PSI B before administration of the cataractogenic insult.
  • Figure 2 is a graph of the transmittance of a cytoplasmic homogenate as a function of temperature (°C) for samples containing 0.0 mM (control), 10 mM, 25 mM, and 50 mM galactose.
  • Figure 3 is a graph of the change in phase separation temperature, Tc(°C), versus concentration (0 to 50 mM) of galactose, WR-77913, and WR- 2721.
  • Figure 4 is a graph of the inhibition of cataract development by WR-77913 compared to controls in animals with streptozotocin-induced diabetic cataract.
  • Figure 5 is a graph of the inhibition of cataract by WR-77913 in animals on a galactose diet.
  • Figure 6 is a graph of the inhibition of cataract development by WR-77913 and by pantethine in animals with selenium-induced cataract.
  • Figure 7 is a graph of the change in phase separation temperature, Tc( ° C), of a calf lens versus concentration of NHS (mM).
  • Figures 8(a) and 8(b) are graphs of the change in phase separation temperature, Tc(°C), versus concentration of succinimide and ethosuximide, respectively, for concentrated lens homogenates.
  • Figure 9 is a graph of the change in phase separation temperature, Tc(°C), versus concentration of succinimide applied to freshly removed whole rat eyes.
  • Figure 10 is a graph of lens transmittance versus temperature (°C) determined following in vivo topical applications of succinimide.
  • Figure 11 is a graph of the change in phase separation temperature, Tc(°C), versus concentration of pantethine in vitro.
  • Figure 12 is a photograph of control rat eyes compared to catarac ⁇ tous rat eyes and rat eyes treated with PSIA prior to selenium injection.
  • Figure 13 is a photograph of control rat eyes compared to catarac- tous rat eyes and rat eyes treated with PSI B prior to selenium injection.
  • Figure 14 is a photograph of control rat eyes compared to catarac- tous rat eyes and rat eyes treated with PSI A in high galactose diet rats.
  • Figure 15 is photograph of control rat eyes compared to cataractous rat eyes and rat eyes treated with PSI A prior to streptozotocin injection.
  • Figure 16 is a photograph of control rat eyes compared to catarac ⁇ tous rat eyes and rat eyes treated with PSI B in RCS rats.
  • Figure 17 is a graph of the effect of PSI A and B on radiation induced cataract.
  • Figure 18 is a graph of the effect of PSI A on selenium induced cataract.
  • Figure 19 is a graph of the effect of PSI B on selenium induced cataract.
  • Figure 20 is a graph of the effect of PSI A and B on galactose induced cataract.
  • Figure 21 is a graph of the effect of PSI A and B on streptozotocin induced cataract.
  • Figure 22 is a graph of the effect of PSI A and B on RCS cataract.
  • Figure 23 is a graph of the change in phase separation temperature, Tc(°C), versus concentration of naturally occurring phase separation inhibitor (arbitrary units and each data point representing the average of duplicative experiments).
  • Figure 24 illustrates the metabolism of pantethine and related compounds, including the conversion of coenzyme A into various metabolites.
  • Figure 25 is a graph depicting the change in phase separation temperature, Tc, versus concentrations of coenzyme A and various derivatives thereof.
  • the present invention is directed to compositions and methods which can inhibit or reverse cataract formation.
  • the compositions and methods will effectively treat cataracts regardless of the source of the cataract.
  • the invention pertains to pharmaceutical reagents or compounds and methods of treatment which lower the phase separation temperature of a lens and which prevent or inhibit the formation of opacities, high molecular weight aggregates, and other physical characteristics of cataracts.
  • the reagents may be administered in a variety of ways, including topically or systemically, as further discussed below. Desirably, the reagents will be able to diffuse into the lens and will be relatively nontoxic to the lens and surrounding tissues, will have little or no adverse effect on the viscoelastic properties of the lens which affect visual acuity, and will desirably have no substantial effect on lens color.
  • the reagents or compounds may initially be screened in vitro for the ability to lower the phase separation temperature of a lens or a lens homogenate.
  • the phase separation temperature of a lens is defined as the temperature at which, at a given protein concentration, the cytoplasm of the lens cells will separate into coexisting phases.
  • the temperature is determined from a coexistence curve in a phase diagram plotting temperature (°C) against protein concentration, where segregation occurs at a temperature and concentration under the curve.
  • a cytoplasmic phase separation is associated with the earliest stages of cataract formation produced by X-irradiation.
  • the phase separation occurs over a narrow temperature range and is characterized by a phase separation temperature, Tc.
  • Tc phase separation temperature
  • the Tc is well below body temperatures and the lenses are transparent.
  • Tc increases during the early stages of cataract formation.
  • membrane function is disrupted, ion levels change, high molecular weight aggregates are formed and an advanced cataract forms.
  • the Tc of a lens may be readily determined by means of laser transmittance, as described, for example, in Clark et al., Invest. Ophthalmol. 22:186, 1982, or in U.S. Patent No.
  • a pair of lenses may be removed from a test animal, one eye of the animal having been X-irradiated and the other eye not.
  • the lenses are placed in a cuvette filled with silicone oil, which is then mounted on a movable, temperature-controlled stage that is directly in the path of a laser beam, with the anterior surface facing the beam.
  • the transmittance can be measured with this apparatus as a function of temperature at every region in the opaque lens. When the transmittance in the region of densest opacity reaches a predetermined percentage of its maximum value, such as 50%, 75%, or 90%, this temperature is defined as the Tc of the normal and irradiated lens during cataract development.
  • phase separation temperature Other methods include light scattering determinations. It should be noted that the value used for Tc will depend on the method used. For instance, with laser transmittance as described above, a value of 50%, 75%, or 90% may be used. Dynamic light scattering, a more sensitive method, may use 90% or 95% of the maximum value, such as described in Benedek et al., Phil. Trans. R. Soc. Lond. A. 293:329- 340, 1979. The maximum value of light scattering was used in Ishimoto et al., Proc. Natl. Acad. Sri. USA 7.6:4414, 1979, to determine Tc, whereas Clark and Benedek, Biochem. Biophvs. Res. Comm. 95:482-489. 1980, used 50% of the maximum value of transmittance. The latter article also describes a method for constructing phase diagrams for isolated lens cytoplasmic homogenate. Each of the foregoing articles is expressly incorporated herein by reference.
  • the reagents of the present invention also inhibit the formation of high molecular weight protein aggregates in the lens.
  • inhibit is meant to include the prevention or reversal of high molecular weight protein aggregate formation in the lens cytoplasm.
  • the extent of protein aggregation in the lens may be determined in vitro by measuring the relative amount of insoluble protein, for example, as described in Osgood et al., Invest. Ophthal. Vis. Sci. 27:1780-1784, 1986, which is incorporated herein by reference.
  • the formation of high molecular weight aggregates may be determined in the intact lens in situ by a number of well-known means, such as by fluctuations in scattered light intensity described in Tanaka and Benedek, Invest. Ophthal.
  • the composition may be administered to an animal by any of several different routes and in a variety of formulations and concentrations, depending on the characteristics of the composition being tested. For instance, a composition may be administered topically or systemically, prior to or following the induction of the cataractic process, such as X-irradiation.
  • the high molecular weight aggregates in the lenses of treated animals may be monitored for a period of time and compared to appropriate untreated controls.
  • Reagent compositions of the invention will desirably inhibit the formation of such aggregates and prevent or delay the further development of cataracts in the treated animals.
  • the lenses of the treated animals may also be removed and the Tc determined as explained above.
  • cataracts caused by X-irradiation, such as described by Clark et al., Invest. Ophthalmol. 21:186, 1982, incorporated by reference herein; (2) cataracts induced by a high galactose diet (galactosemic cataracts), as described in Ishimoto et al., Proc. Natl. Acad. Sci. U.S.A. 76:4414-4416, 1979, incorporated by reference herein; (3) hypoglycemic cataracts in culture, described in Tanaka, Invest. Ophthalmol. Vis. Sci. 24:522-525.
  • the Radiation Model is widely regarded as the model for X- irradiation senile cataract.
  • irradiation is considered to accelerate the aging process and induce senility at a young age.
  • the radiation model is convenient for experimental studies because the time of cataract formation can be controlled by controlling the dose of radiation. Irradiation has many side effects, in addition to cataract, and special care is necessary to maintain the animals. Tc changes during the early stages of cataract formation, and the opacity is associated with loss of soluble protein, hydration, and oxidation of proteins to form high molecular weight aggregates, which are characteristics of human senile cataract.
  • the mature cataract forms approximately 100 days after irradiation.
  • a method for inducing radiation cataracts is as follows: X-ray cataracts are produced in one eye of a New Zealand white rabbit by irradiating the eye with a single 2000 rad (85 kVp, 5 mAmp) dose when the animal is 5 to 6 weeks of age. Under these conditions a mature cataract develops in the irradiated eye 8 to 9 weeks after irradiation.
  • the unirradiated contralateral lens has been found to receive less than 50 rad of irradiation and is used as a control.
  • the animals may receive systemic administration of the drug, for example, or it may be applied topically.
  • the lenses are observed for high molecular weight aggregates and/or cataractous opacification.
  • the irradiated and unirradiated lenses may also be removed from the rabbit eyes.
  • the lenses are placed immediately in silicone oil (Dow Corning 550) and kept at approximately 5°C and the phase separation temperatures are then determined as described above.
  • a mature cataract forms four or five days after a single administration of selenite. While the rapid formation of the cataract makes it a useful model for studies of the effects of PSI, it means that the initiating event is extreme and nonphysiological. Selenite is very toxic and slight overdoses kill the animals. Tc changes during the early stages of cataract formation, and the opacity is associated with increased levels of calcium, which is a common feature in many types of human cataract.
  • the Galactose Model is a model for diabetic cataract in humans. Continuous feeding of a diet that is high in galactose alters the activity of aldose reductase, an enzyme that is involved in diabetes. This model results in very sick animals, and their growth is severely inhibited by the galactose diet. The rate of cataract formation varies in different animals. Tc changes during the early stages of cataract formation and the opacity is associated with changes in glutathione levels, hydration, and formation of high molecular weight aggregates. The mature cataract forms 2-4 weeks after starting the diet.
  • the Streptozotocin Model is associated with the enzyme aldose reductase and is commonly employed as a model for human diabetes.
  • the cataract is induced by a single administration of streptozotocin, rather than continuous feeding.
  • the drug is very toxic and must be administered carefully.
  • the active form of the drug is an anomer so the exact composition of the drug must be carefully controlled.
  • the response of individual animals to the streptozotocin varies widely, and 20%-25% of injected animals often did not form cataracts. Tc changes during the early stages of cataract formation, and the opacity is associated with changes in glutathione levels, hydration, and formation of high molecular weight aggregates. The mature cataract appears approximately 60 days after streptozotocin injection.
  • the Royal College of Surgeons (RCS) Model was developed by the Royal College of Surgeons as an animal model for hereditary cataract in humans.
  • the cataract forms spontaneously 100-120 days after birth.
  • Opacity associated with retinal disease is well known in humans, so the RCS rat remains an important model for human cataract formation.
  • the opacity is associated with the oxidation of lens proteins induced by chemicals released from the abnormal retina.
  • the cataract models mentioned above can generally be classified under four basic categories or types: (1) oxidation, (2) diabetic (aldose reductase), (3) hereditary, and (4) calcium. Under the oxidation heading would fall the radiation and senile cataract models. The galactose and streptozotocin models fall under the diabetic category. The hereditary heading encompasses both the Philly and RCS cataract models. The calcium category includes the selenium cataract model. Each of the four categories represents the formation of cataracts by a different mechanism.
  • the compositions of the present invention in addition to lowering Tc in vitro, prevent or delay the development of cataracts in at least two of the four categories mentioned above.
  • the invention also concerns a method for screening phase separation inhibitors for use as anti-cataractic agents.
  • the compounds listed in Table 1 are exemplary of phase separation inhibitors of the present invention.
  • Phosphorylated Nucleotides Sulfur-containing Compounds adenosine triphosphate (ATP)* glutathione (GSSG)* adenosine diphosphate (ADP)* reduced glutathione (GSH)* adenosine monophosphate (AMP)* cysteine* guanosine triphosphate (GTP)* dithiothreitol (DTT)* uridine triphosphate (UTP)* thiodhistidine thiooctic amides
  • ATP adenosine triphosphate
  • GSG adenosine diphosphate
  • AMP reduced glutathione
  • AMP adenosine monophosphate
  • GTP guanosine triphosphate
  • DTT dithiothreitol
  • UTP uridine triphosphate
  • Vitamins thiouracil thiodiglycol alpha-tocopherol e.g. S-acetyle thiourea
  • pyridoxine HC1
  • sulfonylureas pyridoxal vitamin B6
  • thioureds ascorbic acid vitamin C
  • the compound would then be tested in at least two mechanistically distinct cataract models. If the compound delays or prevents the formation of cataracts in those models, the compound is suitable for treating cataracts of diverse origin within the methods of the present invention.
  • certain phosphorothioate compounds decrease the phase separation temperature of a lens, inhibit the formation of high molecular weight protein aggregates in the lens, and do not substantially affect the viscoelastic properties or color of the lens. Accordingly, these phosphorothioates may be employed to inhibit or prevent cataract development, and further may reverse the early stages of cataract which have developed prior to the initiation of therapy.
  • Some representative phosphorothioate compounds useful in the present invention are described in U.S. Patent No.
  • 3,892,824 which is incorporated by reference herein, and includes, for example, S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate, NH2(CH2)3NHCH2CH2SP ⁇ 3H2, also referred to as WR- 2721.
  • This compound, and hydrates or alkali metal salts thereof, may be synthesized according to the method described in U.S. Patent No. 3,892,824 or other methods which will be known to those skilled in the art.
  • Another phosphorothioate compound preferred in the therapeutic and prophylactic methods herein is S-3-(amino-2-hydroxypropyl) phosphoro ⁇ thioate, NH2CH2CHOHCH2SPO3H2, also referred to as WR-77913.
  • This compound, and hydrates or alkali metal salts thereof, may be synthesized according to the methods described in Piper et al., J. Medical Chem. 12:236-243, 1969, incorporated herein by reference, as well as by other processes which are known to those skilled in the art.
  • a third phosphorothioate useful in the present invention is S-2-(3- methylaminopropylamino) ethyl phosphothioic acid
  • a phosphorothioate compound which may be employed in the methods herein may be selected from the group consisting of S- 2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate, S-3-(amino-2- hydroxypropyl) phosphorothioate, S-2-(3-methylaminopropylamino) ethyl phosphorothioate, and other phosphorothioates which decrease the phase separation temperature of lens cytoplasmic proteins and inhibit the formation of high molecular weight aggregates, and the hydrates and salts thereof.
  • the phosphorothioate useful herein may be of the formula RNHR1SPO3H2, wherein R is hydrogen, an alkyl group containing 1 to 6 carbon atoms, or the group R2NH(C n H2 n )-, in which R2 is hydrogen or an alkyl group containing 1 to 6 carbon atoms; Rj is an optionally substituted alkylene group having from 1 to 6 carbon atoms; or hydrates and/or alkali metal salts thereof.
  • Suitable alkali metal atoms include, for example, sodium, lithium or potassium.
  • optionally substituted alkylene is meant a branched or unbranched saturated hydrocarbon diradical of 1 to 6 carbon atoms, such as, for example:
  • hydrocarbon chain is optionally substituted with 1 to 3 substituents, where examples of such substituted embodiments include hydroxy, halo, trifluoromethyl, alkoxy (-OR, where R is a lower alkyl having 1 to 3 carbon atoms, such as methyl, ethyl or propyl) and -N(R3R4), where R3 and R4 are independently hydrogen or a lower alkyl having 1 to 3 carbon atoms, and the like.
  • the phosphorothioate compounds useful in the present invention may be screened and selected using the procedures herein described.
  • the ability to lower the Tc may be tested in native lenses or lens homogenates.
  • the ability to inhibit the formation of high molecular weight protein aggregates, as well as prophylactic or therapeutic efficacy, may be demonstrated in the appropriate animal models. For example, X-irradiation has been found to increase the phase separation temperature prior to causing the formation of high molecular weight aggregates, serious morphologic damage, and changes in lens permeability and lens transport. These changes are characteristic of many pathologic cataracts.
  • succinimides and derivatives thereof have also been discovered to lower the phase separation temperature and prevent the formation of high molecular weight aggregates and thus are useful in the methods of the present invention.
  • Particularly preferred compounds of the invention include, inter alia, succinimide (C4H5NO2), N- hydroxysuccinimide (C4H5NO3), and ethosuximide (2-ethyl-2- methylsucdnimide, C7H11NO2). These compounds have been found to strongly reduce the phase separation temperatures of solutions comprising concentrated bovine lens nuclear homogenate having a concentration of about 280 mg/ml.
  • Succinimide has also been shown to reduce the phase separation temperature of lenses removed from whole rat eyes following incubation of the freshly extracted eyes in succinimide-containing solutions. Additionally, succinimide has been found to cause reversal of cataracts produced in vivo by sodium selenite.
  • succinimide compounds are known and may be synthesized using protocols familiar to those skilled in the art. Based on the teachings herein, one may screen such compounds for the ability to lower the Tc in vitro, and to inhibit the formation of high molecular weight aggregates in vivo. Appropriate in vivo efficacy and toxicity studies provide the artisan with succinimide compounds which may be formulated as pharmaceutically acceptable agents useful in preventing or treating cataracts.
  • Another class of compounds useful as pharmaceutical compositions for treating cataracts are members of the group pantethine, pantetheine, pantothenic acid, and panthenol. Pantethine has been demonstrated to be a phase separation inhibitor that prevents cataract produced by X-irradiation in vivo.
  • CoA coenzyme A
  • This compound (and derivatives thereof) have been shown to substantially lower the phase separation temperature (Tc) on lens homogenate.
  • Tc phase separation temperature
  • Figure 25 The ability of these compounds to lower Tc is illustrated in Figure 25, where the decrease in phase separation temperature is plotted against the concentration of CoA and various derivatives thereof.
  • CoA-thioesters of the present invention include: glutaryl CoA, glutaconyl CoA, crotonyl CoA, 2-methyl- butyryl CoA, tiglyl CoA, 2-methyl-3-hydroxy-butyryl CoA, 2-methyl-aceto-acetyl CoA, isobutyryl CoA, methacrylyl CoA, 3-hydroxy-isobutyryl CoA, isovaleryl CoA, 3-methyl-crotonyl CoA, trans-3-methyl-glutaconyl CoA, 3-hydroxy-3- methyl-glutaryl CoA, 3-hydroxy-isovaleryl CoA, 3-keto-adipyl CoA, 3-hydroxy propionyl CoA, oxalyl CoA, formyl CoA, beta-alanyl CoA and acrylyl CoA.
  • CoA may also be modified in a variety of manners to yield phase separation inhibitors effective in the prevention and/or inhibition of cataract formation. For example, the following modifications to CoA are included for purposes of illustration:
  • adenosine may be replaced by guanosine, uridin, cytidine, thymidine, or other nucleotide-related bases linked to sugar moieties;
  • the pentose sugar moiety may be replaced with another pentose sugar which is capable of bonding to both adenine and, via a pyrophosphate linkage, to pantetheine;
  • pentose sugar moiety may be replaced by any suitable hexose sugar moiety (see (2) above);
  • the amide bond may be hydrolyzed to leave the adenosine- 3'-phosphate-5'-pyrophosphate linked covalently to pantothenic acid;
  • the terminal S atom may be modified to yield various CoA derivatives, such as acetyl CoA, succinyl CoA and malonyl CoA; (6) the terminal S atom may be linked to various other molecules, such as pantetheine, via a disulfide linkage;
  • the terminal S atom may be linked to another CoA molecule to form di-CoA;
  • other derivatives of pantetheine which are effective phase separation inhibitors may be used in place of pantetheine;
  • various molecules may be constructed by combining one or more of the above features. Additional phosphates may also be added to any of the phosphate-containing compounds identified herein. For example, 4'-(di-, tri-, tetra-, n-)phosphopantothenic acid may function as a phase separation inhibitor, and thus serves as an anti-cataract agent within the present invention. Similarly, the compounds identified in Figure 24 may also be linked to a nucleotide, such as adenosine-3'-phosphate, via a pyrophosphate linkage, and additional or fewer phosphates may be utilized.
  • a nucleotide such as adenosine-3'-phosphate
  • all of the compounds disclosed herein which contain terminal sulfur groups may be effective phase separation inhibitors in either the sulfhydryl (-SH) or disulfide (-S-S-) form.
  • metabolites of CoA may also serve as phase separation inhibitors within the present invention. Examination of CoA reveals that pantetheine (the sulfhydryl form of pantethine) is a sub-component of CoA, and is linked via a diphosphate to adenosine-3'-phosphate.
  • These metabolites of CoA, including pantetheine and the adenosine mono-, di- and tri-phosphates are effective phase separation inhibitors.
  • the compounds listed in Figure 24 are representative examples of metabolites of CoA.
  • nicotinamide adenine dinucleotide NAD +
  • NAD + as well as the related NADH, NADP + , NADPH, and flavin adenine dinucleotide may generally be characterized as containing one or more of the following components: (1) a purine-containing compound, (2) a pentose or other sugar, (3) a single or multiphosphate linkage, (4) a pentose or other sugar, and (5) a pyrinidine-containing compound.
  • a purine-containing compound (2) a pentose or other sugar, (3) a single or multiphosphate linkage, (4) a pentose or other sugar, and (5) a pyrinidine-containing compound.
  • phase separation inhibitors may be formed by cleavage of the single- or multi-phosphate linkages found in the above compounds, including the following compounds: AMP, ADP, ATP, GMP, GDP, GTP, CMP, CDP, CTP, UMP, UDP, UTP, TMP, TDP and TTP.
  • PAP adenosine-3',5'-diphosphate
  • APS adenylyl-sulfate
  • PAPS 3'- phosphoadenylyl sulfate
  • cyclic AMP may also serve as effective phase separation inhibitors, and thus serve to prevent or inhibit cataract formation in vivo.
  • addition of one or more phosphates to a molecule can improve its ability to function as a phase separation inhibitor (i.e., lower Tc) in vitro.
  • Tc phase separation inhibitor
  • addition of phosphate to glucose i.e., conversion of D-(+)-glucose to D-glucose-1-phosphate
  • Tc time separation inhibitor
  • addition of one or more phosphate moieties, or linking two molecules via a phosphate linkage yields improved phase separation inhibitors.
  • Important elements for the successful use of the reagent composi ⁇ tions are the selection of the mode and dosage of administration as well as the timing of administration.
  • the animal which is to be treated may also be an important consideration.
  • dosages may be higher in veterinary applications, such as for horses, dogs and cats, and may be more prolonged than might be possible or desirable with humans.
  • the reagent composition should be applied before the formation of detectable levels of the high molecular weight protein aggregates, although it may also be applied up to and including the time that vision is noticeably impaired. It should also be applied as soon as possible after detection of any rise in phase separation temperature. Dosage is determined by the mode of administration. Administration of the active compounds and acceptable salts thereof can be via any of the accepted modes of administration for agents (or the pharmaceutically active metabolites thereof) which may be absorbed by the lens of the eye. These methods include topical, oral, parenteral and otherwise systemic or aerosol forms. Local or topical application in an acceptable physiological buffer may be preferred since a lower total dosage may be required.
  • the composi- tions used may be in the form of solid, semisolid, or liquid dosage forms, such as, for example, ointments, tablets, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages.
  • the compositions will include a conventional pharmaceutical carrier or excipient and an active compound or the pharmaceutically acceptable salts thereof and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.
  • more than one pharmaceutically active reagent may be included in the compositions to achieve advantages not available from the separate administration of such reagents.
  • the amount of active compound administered will, of course, be dependent on the subject being treated, the stage of cataract development, the source of the cataract, the manner of administration and the judgment of the prescribing physician (or veterinarian).
  • the amount required for effective prophylaxis or treatment may also be determined by measuring the decrease in phase separation temperature per mole. For in vivo application, it is necessary to decrease and maintain the phase separation temperature at less than body temperature while inhibiting the formation of high molecular weight aggregates.
  • an effective dosage of a phosphorothioate composi ⁇ tion such as WR-77913, may be in the range of 10 to 2,000 mg/kg/day, preferably 50 to 1500 mg/kg/day if administered systemically. For an average 70 kg human, this would amount to 700 mg to 14 g/day, or preferably 3.5 to 10.5 g/day.
  • Localized application via, e.g., topical preparations may reduce the dose accordingly.
  • Parenteral administration of the pharmaceutical reagent composi ⁇ tions is generally characterized by injection, either subcutaneously, intramuscu ⁇ larly or intravenously.
  • Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
  • Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like.
  • compositions to be administered may also contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and the like, such as, for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
  • nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and the like, such as, for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
  • nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like, may be used.
  • Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc., an active reagent compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
  • the composition or formulation to be administered will, in any event, contain a quantity of the active compound(s) in an amount effective to inhibit the further development of cataracts in the subject being treated.
  • a pharmaceutically acceptable nontoxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • excipients such as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations, and the like.
  • Such compositions may contain 10%-95% active ingredient, preferably 25%-70%.
  • Another approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained. See, e.g, U.S. Patent No. 3,710,795.
  • Lacrimal fluid is isotonic with blood, having an isotonicity value corresponding to that of a 0.9% sodium chloride solution.
  • an ophthalmic solution should have this isotonicity value, but the eye can tolerate isotonicity values as low as that of a 0.6% sodium chloride solution and as high as that of a 2.0% sodium chloride solution without marked discomfort.
  • Some ophthalmic solutions are necessarily hypertonic in order to enhance absorption and provide a concentration of the pharmaceutically active ingredient(s) strong enough to exert a prompt and effective action.
  • a boric acid vehicle which is preferred in some ophthalmic preparations has a pH slightly below 5.0. It may be prepared by dissolving 1.9 g of boric acid in sufficient water to make 100 mL of solution. A phosphate buffer system may also be employed, and adjusted for isotonicity provides a choice of pH ranging from 5.9 to 8.0. A pharmaceutical grade of methylcellulose (e.g., 1% if the viscosity is 25 centipoises, or 0.25% if 4000 centipoises) or other suitable thickening agents such as hydroxypropyl methylcellulose or polyvinyl alcohol occasionally are added to ophthalmic solutions to increase the viscosity and prolong contact of the drug with the tissue.
  • methylcellulose e.g., 1% if the viscosity is 25 centipoises, or 0.25% if 4000 centipoises
  • suitable thickening agents such as hydroxypropyl methylcellulose or polyvinyl alcohol occasionally are added to o
  • Animal Irradiation Gamma irradiation was performed with a Cs- 137 teletherapy unit fitted with an 18 x 18 cm collimator. Irradiated animals received a single exposure of 15.3 Gy (0.63 Gy/rnin). Rats were unanesthetized and positioned in wedge-shaped lucite restraining devices so that the entire head was under the collimator. Dosimetry was measured with a 100 R ionization chamber. Sham-irradiated aging control animals were treated similarly to irradiated animals but without exposure to radiation.
  • Rats from each group were sacrificed in ether chambers up to 210 days after receiving treatments, and the eye enucleated and placed on ice. Lenses were dissected from the eye within 30 minutes and weighed. To study the content and molecular weight distribution of rat lens proteins, extracts were prepared by homogenizing individual lenses in 1 ml Wheaton homogenizers (Wheaton, Millwood, N.J.) with 0.5 ml of 0.10 M sodium sulfate/0.02 M potassium phosphate elution buffer (pH 6.9). The lense homogenate was transferred to microcentrifuge vials and the homogenizers rinsed twice with 0.25 ml of elution buffer.
  • Wheaton homogenizers Wood, N.J.
  • Figure 1 is a photographic representation of the protective effect that WR-77913 (PSI A) and pantethine (PSI B) had against cataract formation in X-irradiated rat lenses.
  • Anterior and slit-lamp views of rat eyes from control, irradiated, and irradiated and drug-treated animals are shown 154 days after treatment.
  • Control rat lenses remained transparent throughout the study.
  • Irradiated rats which received no drug treatment developed moderate lenticular opacities within 90 days of receiving gamma radiation. Lens opacification progressed to mature cataracts by 120 days post-irradiation in all animals which received no WR-77913 or pantethine.
  • Rats protected by WR-77913 or pantethine were noted to have only very slight lenticular opacities when photographed 154 days after irradiation. The appearance of the lens in the drug-treated rats remained stable until the animals were sacrificed at 210 days post-irradiation.
  • the following example demonstrates the effect of two phosphorothioate compounds, WR-77913 and WR-2721, on the phase separation temperature of homogenates of lens tissue.
  • the measurement of dTc/dC, the difference in phase separation temperature produced by the reagent, is useful as a method for identifying potential reagents for preventing cataract in vivo.
  • the samples were gently homogenized to mix the additives with the homogenate. Preliminary studies showed that dilutions of 10% or less produced no additional background scattering and that the change in Tc was attributable to the addition of chemical reagents and was not simply the effect of dilution. The concentrations reported in the results were the final concentrations of the chemicals in the homogenates. The Tc values were measured over a concentration range between 0 mM and 50 mM for each reagent.
  • Tc Phase Separation Temperature
  • Determination of dTc/dC The effect of the chemical on Tc is defined as the change in Tc, with change in concentration of the chemical repre- sented by dTc/dC.
  • the Tc of the control which contained only water, and the decrease in Tc produced by the chemical additives were determined.
  • the mean decrease in Tc and the standard deviation were determined for each concentra ⁇ tion.
  • a linear regression was used to determine the best linear fit of the data and the correlation coefficient.
  • the slope of the line was defined as dTc/dC.
  • Figure 2 depicts a concentration series used to determine the decrease in Tc at various concentrations of a reagent.
  • the results were obtained using galactose, prepared essentially as described above for the phosphorothioates.
  • galactose prepared essentially as described above for the phosphorothioates.
  • rats a diet rich in galactose results in cataract formation, presumably via the aldose reductase pathway similar to that of the diabetic cataract.
  • mice which do not form cataract when fed a diet rich in galactose, it has been discovered that the high galactose diet delays formation of cataracts after irradiation.
  • the transmittance of the cytoplasmic homogenate was plotted as a function of the temperature of the lens.
  • the transmittance of the cytoplasmic homogenate was plotted as a function of the temperature for samples containing 0.0 mM (control), 10 mM, 25 mM, and 50 mM galactose.
  • the Tc was 15.6 °C in the control, 15.0° C in the sample containing 10 mM galactose, 13.8 °C in the sample containing 25 mM galactose, and 12.4 °C in the sample containing 50 mM galactose.
  • Figure 3 shows the decrease in Tc produced by galactose, WR- 77913, and WR-2721 over the concentration range of 0 to 50 mM.
  • the slopes of the regression lines through the data are the dTc/dC for each compound.
  • dTc/dC was -65°C/mole for galactose, -28°C/mole for WR-77913, and -76°C/mole for WR-2721.
  • the correlation coefficient was 0.997 for the galactose data, 0.800 for WR-77913, and 0.993 for WR-2721.
  • WR-77913 was administered by i.p. injection 30 minutes prior to initiation of diabetic cataract by injection of 60 mg streptozotocin.
  • the WR- 77913 was administered as a single injection of 1160 mg/kg in PBS buffer. Mature cataracts were observed in the streptozotocin-treated animals approximately 42 days after injection. Mature cataracts were not observed in the WR-77913-treated animals.
  • streptozotocin was dissolved in sterile sodium citrate, pH 5.0, to a concentration of 20 mg/ml.
  • the streptozotocin solution was injected intravenously into the femoral vein of eight 5-week-old male Sprague-Dawley rats, such that each animal received a dose of 55 mg/kg of body weight.
  • Half of the animals were injected i.p. with 1160 mg/kg of WR-77913 30 minutes prior to receiving streptozotocin.
  • Stages 1 through 6 Animals were examined weekly with a slit-lamp biomicroscope for evidence of cataract development and staged according to the criteria of Sasaki et al., Opthalmic Res. 15:185-190, 1983, incorporated by reference herein. Under these criteria, the cataracts are classified as stages 1 through 6 on the basis of the appearance of the lens using a slit lamp. Stages 1 and 2 represent very slight changes in the lens without opacity. Stage 3 shows initial opacity. Stage 4 shows moderate opacity. Stage 5 is intense opacity involving much, but not all, of the lens. Stage 6 is a mature cataract in which the opacity involves the entire lens. The results of this experiment are shown graphically in Figure 4.
  • WR-77913 was administered to rats that were induced to form galactosemic cataract.
  • WR-77913 was administered by i.p. injection at a dose of 450 mg/Kg every 2 days after the galactosemic diet was initiated. Ten days after starting the galactosemic diet, cataract appeared in the rats not receiving the
  • WR-77913 was administered to X-irradiated animals 30 minutes following irradiation.
  • the WR-77913 was administered as a single i.p. injection at a dose of 1160 mg/kg. After 90 days, cataract appeared in the animals which did not receive WR-77913. No cataract was observed in animals treated with WR-77913.
  • WR-77913 was administered locally as eyedrops to the eyes of X- irradiated rats 60 minutes prior to X-irradiation.
  • the eyedrops contained 600 mg/ml WR-77913 in PBS.
  • the total amount of compound was about 0.5 ml, or about 1200 mg/kg.
  • X-irradiation-induced cataracts appeared in the rats not receiving WR-77913, but no opacities were observed in the WR-77913-treated rats.
  • WR-2721 is an amino-phosphorothioate similar to WR-77913, which decreases the phase separation temperature, as shown in Figure 3.
  • a single i.p. injection of 500 mg/kg WR-2721 15 minutes prior to X-irradiation prevented formation of cataracts.
  • the effect of WR-2721 is very similar to that of WR-77913 in the sense that it also prevented hydration, formulation of high molecular aggregates, and loss of soluble protein.
  • test lens and control lens were placed in aqueous solutions containing 0.1 M phosphate buffer, 2% dimethyl sulf oxide (DMSO) at pH 7.0.
  • the solution containing the test lense also contained a controlled amount of N- hydroxysuccinimide (NHS) ranging from 0-80 mM in concentration.
  • NHS N- hydroxysuccinimide
  • the difference (-Tc) between the phase separation temperature of the test lens and the control was measured as a function of NHS concentration.
  • the decrease in phase separation temperature (-Tc) in the calf lens is plotted in Figure 7 as ordinate versus NHS concentration in mM plotted as abscissa.
  • Bovine lenses treated with NHS preparations for 40 hours in vitro have phase separation temperatures as much as 10 °C below that of a control lens, even following extensive dialysis of the lens, demonstrating the permanency of Tc suppression by NHS.
  • Topical NHS Lowers the Phase Separation Temperature of the Lens In Vivo
  • Concentrated bovine nuclear homogenate was assayed to be approximately 280 mg/ml.
  • Solutions of succinimide and ethosuximide in phosphate buffer (0.1 M, pH 7) were prepared by having concentrations of 1.2, 0.8, 0.6, 0.4, 0.2, 0.08, and 0.04 M.
  • Ten microliters of the succinimide solutions were added to a first set of 90 microliter samples of the concentrated nuclear homogenate.
  • Ten microliters of the ethosuximide solutions were added to a second set of 90 microliter samples of the concentrated nuclear homogenate.
  • the resulting solutions were found to be about 252 mg/ml, and the resultant succinimide and ethosuximide concentrations were about 120, 80, 60, 40, 20, 8, and 4 mM.
  • a control sample was prepared by adding 10 microliters of buffer to 90 microliters of concentrated nuclear homogenate.
  • the Tc in the lenses treated with succinimide was found to be about 3.5 °C lower than the Tc of lenses treated with the PBS control.
  • Concentrated bovine nuclear homogenate was assayed to be approximately 280 mg/ml.
  • Ten microhter samples of the pantethine solutions were added to a second set of 90 microliter samples of concentrated bovine nuclear homogenate.
  • a control sample was prepared by adding 10 microliters of buffer solution to 90 microliters of concentrated bovine nuclear homogenate.
  • FIG 12 illustrates WR-77913 (PSI A) as an effective inhibitor of selenite cataract.
  • PSI A was administered as a single i.p. injection of approximately 600 mg/kg 15 minutes prior to selenite injection.
  • FIG. 14 illustrates inhibited cataract formation by WR-77913 (PSI A) on high galactose diet cataract. The photographs were taken approxi ⁇ mately 3 weeks after starting the diet. PSI A was administered as a 300 mg i.p. injection every other day for 3 weeks. EXAMPLE 21
  • WR-77913 prevented cataract in the majority of animals injected with streptozotocin. This is illustrated in Figure 15. The photographs were taken approximately 70 days after injection of streptozotocin. PSI A was administered as a single i.p. injection of approximately 1160 mg/kg 30 minutes prior to injection with streptozotocin.
  • Figure 16 depicts the inhibitory effect of pantethine (PSI A) on PSI A
  • RCS cataract The photographs were taken approximately 6 months after birth of the RCS animals. Eighty percent of the RCS animals which were not administered PSI B formed cataracts. PSI B protected 75% of the animals. PSI B was administered as a 300 mg i.p. injection once a week for the life of the animal.
  • each vertical bar represents the cataract stage in a single animal.
  • Figure 17 illustrates the effect of PSI A on X-irradiated cataract.
  • mature (stage 6) cataracts were observed 150 days after animals were irradiated.
  • Animals treated with PSI A did not opacity.
  • Figure 18 depicts the effect of PSI A on selenium cataract.
  • PSI A inhibited cataract formation in all animals injected with selenium. In the absence of PSI, all animals formed mature cataracts 4 days after administration of selenium.
  • Figure 19 shows the effect of PSI B on selenium cataract.
  • PSI B inhibited cataract formation in all animals injected with selenium. In the absence of PSI, all animals formed mature cataracts 5 days after administration of selenium.
  • Figure 20 illustrates the effect of PSI A and B on galactose cataract 14 days after starting a galactose diet. PSI A had some inhibitory effect. PSI B was inhibitory in the galactose model. Observations were made approximately 14 days after start of the galactose diet.
  • Figure 21 depicts the effect of PSI A and B on streptozotocin cataract. PSI A inhibited cataract formation induced by streptozotocin. PSI B was less effective in inhibiting the streptozotocin cataract.
  • FIG. 22 shows the effect of PSI B on RCS cataract.
  • PSI B prevented cataract in approximately 2/3 of RCS animals 123 days after the animals were born.
  • the eyes of the injected animals were examined daily using a slit-lamp biomicroscope for 7 days. Animals which received selenite only and no panthenol formed mature, stage 5 cataracts within 1 week of injection. Animals receiving the panthenol did not advance beyond stage 2.
  • the eyes of the injected animals were examined daily using a slit-lamp biomicroscope for 7 days. Animals which received selenite only and no cysteamine formed mature, stage 5 cataracts within 1 week of injection. Animals receiving the cysteamine did not advance beyond stage 2.
  • FIG. 23 shows the strong inhibitory effect of the natural compound. The compound was added to lens homogenate as described in Example 2.
  • the substance was extracted from a lens homogenate which was centrifuged at approximately 250,000 g and the soluble supernatant filtered through a filter having a 2000 MW cutoff. It was important to prepare the homogenate without added buffer or salt, at physiological pH (7.0 - 7.2).
  • the active compound is believed to be a metabolite in anaerobic glycolysis and is inactivated by a protease. On this basis, it is expected that the active compound may also be present in other natural sources including yeast and bacteria.
  • a natural reagent may have a variety of advantages: toxicity is less of a problem with a synthetic phase separation inhibitor; natural reagents may provide additional insight into the action of the phase inhibitors, in vivo; and natural reagents provide simple model compounds that can be modified to increase anti-cataract activity.
  • the results illustrated in the above examples indicate that natural and physiologically compatible reagents have the potential to protect against and reverse cataract formation by acting as phase separation inhibitors.
  • reagents of the present invention have been described with reference to traditional methods of administration, such as drops into the eye, in tablet form or by injection, other means familiar to those skilled in the art of drug delivery could be utilized.
  • drug encapsulated in polymer matrices could be implanted into or adjacent the eye for sustained linear release over time.
  • Either degradable (for example, polyanhydrides, polyorthoesters, and polylactic acids) or nondegradable (for example, ethylene vinyl acetate and polystyrene) polymers could be used.
  • Drug could also be injected directly into the aqueous humor, such as by microinjection. Modifications and variations of the present invention, including methods and reagents for the prevention or reversal of cataract formation, will be obvious to those skilled in the art from the foregoing detailed description. Such modifications and variations are intended to come within the scope of the appended claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compositions permettant de réduire la température de séparation de phases et d'inhiber la formation d'agrégats ayant une masse molaire élevée dans des lentilles oculaires, ceci ayant pour effet d'inhiber ou d'inverser la formation de cataracte.
PCT/US1993/004452 1993-05-12 1993-05-12 Prevention ou inversion chimique de la cataracte par inhibiteurs de separation de phases WO1994026259A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU43723/93A AU4372393A (en) 1993-05-12 1993-05-12 Chemical prevention or reversal of cataract by phase separation inhibitors
PCT/US1993/004452 WO1994026259A1 (fr) 1993-05-12 1993-05-12 Prevention ou inversion chimique de la cataracte par inhibiteurs de separation de phases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1993/004452 WO1994026259A1 (fr) 1993-05-12 1993-05-12 Prevention ou inversion chimique de la cataracte par inhibiteurs de separation de phases

Publications (1)

Publication Number Publication Date
WO1994026259A1 true WO1994026259A1 (fr) 1994-11-24

Family

ID=22236587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/004452 WO1994026259A1 (fr) 1993-05-12 1993-05-12 Prevention ou inversion chimique de la cataracte par inhibiteurs de separation de phases

Country Status (2)

Country Link
AU (1) AU4372393A (fr)
WO (1) WO1994026259A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3006217A1 (de) * 1979-02-20 1980-09-04 Chugai Pharmaceutical Co Ltd Verfahren zum nachweis von krebserkrankungen und reagens zur durchfuehrung des verfahrens
US4499074A (en) * 1983-08-29 1985-02-12 Sanofi Method for the therapeutic utilization of Coenzyme A
WO1988009660A2 (fr) * 1987-06-04 1988-12-15 Massachusetts Institute Of Technology Prevention ou inversion chimique de la cataracte a l'aide d'inhibiteurs de separation de phase
SU1475336A1 (ru) * 1986-11-18 1990-09-23 Ростовский-На-Дону Государственный Научно-Исследовательский Противочумный Институт Способ определени формы холерных вибрионов
WO1992000960A1 (fr) * 1990-07-06 1992-01-23 University Of New Mexico Utilisation de beta-alethine pour des cultures cellulaires et a des fins therapeutiques
US5091421A (en) * 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
WO1993020805A1 (fr) * 1992-04-13 1993-10-28 Oculon Corporation Prevention ou inversion chimique de la cataracte a l'aide d'inhibiteurs de separation de phase

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3006217A1 (de) * 1979-02-20 1980-09-04 Chugai Pharmaceutical Co Ltd Verfahren zum nachweis von krebserkrankungen und reagens zur durchfuehrung des verfahrens
US4499074A (en) * 1983-08-29 1985-02-12 Sanofi Method for the therapeutic utilization of Coenzyme A
SU1475336A1 (ru) * 1986-11-18 1990-09-23 Ростовский-На-Дону Государственный Научно-Исследовательский Противочумный Институт Способ определени формы холерных вибрионов
WO1988009660A2 (fr) * 1987-06-04 1988-12-15 Massachusetts Institute Of Technology Prevention ou inversion chimique de la cataracte a l'aide d'inhibiteurs de separation de phase
US5091421A (en) * 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
WO1992000960A1 (fr) * 1990-07-06 1992-01-23 University Of New Mexico Utilisation de beta-alethine pour des cultures cellulaires et a des fins therapeutiques
WO1993020805A1 (fr) * 1992-04-13 1993-10-28 Oculon Corporation Prevention ou inversion chimique de la cataracte a l'aide d'inhibiteurs de separation de phase

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A.J. BRON ET AL.: "Medical treatment of cataract", EYE, vol. 1, no. 5, 1985, pages 524 - 550 *
A.V. BOGATIREV ET AL.: "Chemical protection of newborn mice against ionizing radiation", RADIOBIOLOGIYA, vol. 12, no. 3, 1972, pages 454 - 458 *
DATABASE WPI Week 9117, Derwent World Patents Index; AN 91-123712 *
H. NISHIGORI ET AL.: "Effect of MPG on glucocorticoid-induced cataract formation in developing chick embryo", INVEST. OPHTHALMOL. VIS. SCI., vol. 25, no. 9, 1984, pages 1051 - 1052 *
S. TSUTSUMI ET AL.: "Wirkung von Pantothensäurederivaten auf den durch Hyperlaktosediät hervorgerufenen Katarakt in Ratten", DEUTSCHE APOTHEKERZEITUNG, vol. 108, no. 33, 1968, pages 1204 *

Also Published As

Publication number Publication date
AU4372393A (en) 1994-12-12

Similar Documents

Publication Publication Date Title
FI94924B (fi) Menetelmä antimikrobisesti vaikuttavan säilytyssysteemin valmistamiseksi oftalmologisesti hyväksyttäviä lääkeaineita varten
US5338545A (en) Chemical prevention or reversal of cataract by phase separation inhibitors
US5401880A (en) Chemical prevention or reversal of cataract by phase separation inhibitors
AU735684B2 (en) Method of treating dry eye disease with purinergic receptor agonists
US5284874A (en) Chemical prevention or reversal of cataract by phase separation inhibitors
US6416794B1 (en) Methods and compositions for treating cataracts using substances derived from yeast or saltbush
RU2102069C1 (ru) Фармацевтическая композиция для лечения глаукомы
US5037851A (en) Use of acetyl l-carnitine in the therapeutic treatment of cataract, and pharmaceutical compositions useful in such treatment
Gerster Antioxidant vitamins in cataract prevention
AU2011259997A8 (en) N-acetyl-DL-leucine, neuroprotective and retinoprotective medicament
Xu et al. Establishment of a naphthalene cataract model in vitro
US5091421A (en) Chemical prevention or reversal of cataract by phase separation inhibitors
US5290813A (en) Chemical prevention or reversal of cataract by phase separation inhibitors
Gehring et al. The cataractogenic activity of chemical agents
US4797422A (en) Pharmaceutical compounds effective against several disorders of the eye in particular the cataract and composition containing them
Goldsmith Molecular biology and molecular pathology of a newly described molecular disease–tyrosinemia II (the Richner-Hanhart syndrome)
IT9020968A1 (it) Composto farmaceutico a base di un antocianidina per il trattamento di malattie oftalmiche
WO1994026259A1 (fr) Prevention ou inversion chimique de la cataracte par inhibiteurs de separation de phases
RU2035180C1 (ru) Антивирусное средство
Ubels et al. Retinoid permeability and uptake in corneas of normal and vitamin A-deficient rabbits
WO1991010427A2 (fr) Effet de l'inhibition de la transglutaminase sur le developpement des microfilaires et sur la viabilite des macrofilaires
EP0538911A2 (fr) Prevention ou inversion chimique de la cataracte à l'aide d'inhibiteurs de séparation de phase
AU623082B2 (en) Chemical prevention or reversal of cataract by phase separation inhibitors
EP0885612A1 (fr) La pirenoxine dans le traitement topique des conditions inflammatoires
EP0397437A1 (fr) Méthode pour le traitement des yeux humains et composition à cette fin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP KR NO NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载